Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
BC-U001 is an allogeneic fresh human umbilical cord-derived mesenchymal stem cell product,
which showed therapeutic potential for rheumatoid arthritis(RA) based on its
anti-inflammatory, immunomodulatory and tissue repair activities. The primary objective of
this open-label, non-randomized, dose-escalation study is to evaluate the safety and
tolerability of a single intravenous infusion of BC-U001 for RA patients using a 3+3 design.